Literature DB >> 28736085

Low cardiac output syndrome in the postoperative period of cardiac surgery. Profile, differences in clinical course and prognosis. The ESBAGA study.

J L Pérez Vela1, J J Jiménez Rivera2, M Á Alcalá Llorente3, B González de Marcos4, H Torrado5, C García Laborda6, M D Fernández Zamora7, F J González Fernández8, J C Martín Benítez9.   

Abstract

OBJECTIVES: An analysis is made of the clinical profile, evolution and differences in morbidity and mortality of low cardiac output syndrome (LCOS) in the postoperative period of cardiac surgery, according to the 3 diagnostic subgroups defined by the SEMICYUC Consensus 2012.
DESIGN: A multicenter, prospective cohort study was carried out.
SETTING: ICUs of Spanish hospitals with cardiac surgery. PATIENTS: A consecutive sample of 2,070 cardiac surgery patients was included, with the analysis of 137 patients with LCOS.
INTERVENTIONS: No intervention was carried out.
RESULTS: The mean patient age was 68.3±9.3 years (65.2% males), with a EuroSCORE II of 9.99±13. NYHA functional class III-IV (52.9%), left ventricular ejection fraction<35% (33.6%), AMI (31.9%), severe PHT (21.7%), critical preoperative condition (18.8%), prior cardiac surgery (18.1%), PTCA/stent placement (16.7%). According to subgroups, 46 patients fulfilled hemodynamic criteria of LCOS (group A), 50 clinical criteria (group B), and the rest (n=41) presented cardiogenic shock (group C). Significant differences were observed over the evolutive course between the subgroups in terms of time subjected to mechanical ventilation (114.4, 135.4 and 180.3min in groups A, B and C, respectively; P<.001), renal replacement requirements (11.4, 14.6 and 36.6%; P=.007), multiorgan failure (16.7, 13 and 47.5%), and mortality (13.6, 12.5 and 35.9%; P=.01). The mean maximum lactate concentration was higher in cardiogenic shock patients (P=.002).
CONCLUSIONS: The clinical evolution of these patients leads to high morbidity and mortality. We found differences between the subgroups in terms of the postoperative clinical course and mortality.
Copyright © 2017 Elsevier España, S.L.U. y SEMNIM. All rights reserved.

Entities:  

Keywords:  Cardiac surgery; Cirugía cardíaca; ESBAGA; Evolución; Evolution; Low cardiac output syndrome; Prognosis; Pronóstico; Síndrome de bajo gasto cardíaco

Mesh:

Substances:

Year:  2017        PMID: 28736085     DOI: 10.1016/j.medin.2017.05.009

Source DB:  PubMed          Journal:  Med Intensiva (Engl Ed)        ISSN: 2173-5727


  7 in total

1.  The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft: a systematic review and meta-analysis.

Authors:  Wanyu Wang; Xiaoshuang Zhou; Xinyang Liao; Bin Liu; Hai Yu
Journal:  J Anesth       Date:  2019-04-25       Impact factor: 2.078

2.  Prognostic Value of Late Gadolinium Enhancement in Postoperative Morbidity following Mitral Valve Surgery in Rheumatic Mitral Stenosis.

Authors:  Teuku Muhammad Haykal Putra; Renan Sukmawan; Elen Elen; Celly A Atmadikoesoemah; Dwita Rian Desandri; Manoefris Kasim
Journal:  Int J Angiol       Date:  2019-08-06

3.  Preemptive renal replacement therapy in post-cardiotomy cardiogenic shock patients: a historically controlled cohort study.

Authors:  Guo-Wei Tu; Jia-Rui Xu; Lan Liu; Du-Ming Zhu; Xiao-Mei Yang; Chun-Sheng Wang; Guo-Guang Ma; Zhe Luo; Xiao-Qiang Ding
Journal:  Ann Transl Med       Date:  2019-10

4.  Outcomes and risk factors of postoperative hepatic dysfunction in patients undergoing acute type A aortic dissection surgery.

Authors:  Wei Zhou; Guokun Wang; Yaoyang Liu; Yun Tao; Zhen Du; Yangfeng Tang; Fan Qiao; Yang Liu; Zhiyun Xu
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

5.  VDI pacing with temporary esophageal and transvenous pacemaker leads to treat post-cardiac surgery cardiogenic shock.

Authors:  Sameer Sharif; Adel Dyub; Craig Ainsworth
Journal:  J Cardiothorac Surg       Date:  2022-05-03       Impact factor: 1.522

6.  Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice.

Authors:  Fabio Guarracino; Matthias Heringlake; Bernard Cholley; Dominique Bettex; Stefaan Bouchez; Vladimir V Lomivorotov; Angela Rajek; Matti Kivikko; Piero Pollesello
Journal:  J Cardiovasc Pharmacol       Date:  2018-01       Impact factor: 3.105

7.  Preemptive renal replacement therapy in post-cardiotomy cardiogenic shock patients: a new concept?

Authors:  Jean-Pierre Quenot; Marine Jacquier; Auguste Dargent; Jean-Baptiste Roudaut; Pascal Andreu; François Aptel; Marie Labruyère; Saber Barbar
Journal:  Ann Transl Med       Date:  2020-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.